Identification of 5-Iodotubercidin as a Genotoxic Drug with Anti-Cancer Potential

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Xin ^a   Jia, Deyong ^a   Liu, Huijuan ^a   Zhu, Na ^a   Zhang, Wei ^a   Feng, Jun ^a   Yin, Jun ^a   Hao, Bin ^a   Cui, Daxiang ^a   Deng, Yuezhen ^b   Xie, Dong ^b   He, Lin ^a   Li, Baojie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODOTUBERCIDIN; ATM PROTEIN; CHECKPOINT KINASE 2; HISTONE GAMMA H2AX; ISOMERASE; NUCLEAR PROTEIN; PROTEIN P53; PROTEIN TOPBP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CARCINOMA; CELL CYCLE S PHASE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENOTOXICITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL DEATH; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MUTAGENS; S PHASE; TUBERCIDIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877142929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062527     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H, (2011) Towards novel paradigms for cancer therapy. Oncogene 30: 1-20.
3. Tennant DA, Duran RV, Gottlieb E, (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
4. Ewald B, Sampath D, Plunkett W, (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27: 6522-6537.
5. Shen Z, (2011) Genomic instability and cancer: an introduction. J Mol Cell Biol 3: 1-3.
6. Wang Z, Li B, (2010) Mdm2 links genotoxic stress and metabolism to p53. Protein Cell 1: 1063-1072.
7. Shiloh Y, (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155-168.
8. Jackson SP, Bartek J, (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078.
9. Zannini L, Buscemi G, Kim JE, Fontanella E, Delia D, (2012) DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. J Mol Cell Biol. 4: 294-303.
10. Wang X, Zeng L, Wang J, Chau JF, Lai KP, et al. (2011) A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 18: 5-15.
11. Chau JF, Jia D, Wang Z, Liu Z, Hu Y, et al. (2012) A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nat Commun 3: 836.
12. Vousden KH, Lane DP, (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
13. Farnebo M, Bykov VJ, Wiman KG, (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396: 85-89.
14. Ma G, Li L, Hu Y, Chau JF, Au BJ, et al. (2012) A typical Atm-p53 genetic interaction in osteogenesis is mediated by Smad1 signaling. J Mol Cell Biol 4: 118-120.
15. Lane DP, Cheok CF, Lain S, (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2: a001222.
16. Chene P, (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
17. Lai KP, Leong WF, Chau JF, Jia D, Zeng L, et al. (2010) S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 29: 2994-3006.
18. Massillon D, Stalmans W, van de Werve G, Bollen M, (1994) Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J 299: 123-128.
19. Ugarkar BG, DaRe JM, Kopcho JJ, Browne CE III, Schanzer JM, et al. (2000) Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J Med Chem 43: 2883-2893.
20. Golembiowska K, White TD, Sawynok J, (1995) Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors. Brain Res 699: 315-320.
21. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
22. Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM, (1980) Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 40: 2142-2146.
23. Zimmermann J, Hajibabaei M, Blackburn DC, Hanken J, Cantin E, et al. (2008) DNA damage in preserved specimens and tissue samples: a molecular assessment. Front Zool 5: 18.
24. Wilson PM, Labonte MJ, Russell J, Louie S, Ghobrial AA, et al. (2011) A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates. Nucleic Acids Res 39: e112.
25. Shangary S, Wang S, (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
26. Li T, Ren G, Lusardi T, Wilz A, Lan JQ, et al. (2008) Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest 118: 571-582.
27. Boison D, (2010) Adenosine dysfunction and adenosine kinase in epileptogenesis. Open Neurosci J 4: 93-101.
28. Lukas J, Lukas C, Bartek J, (2011) More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 13: 1161-1169.
29. Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, et al. (2011) 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol 13: 243-253.
30. Ewald B, Sampath D, Plunkett W, (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6: 1239-1248.
31. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, et al. (2006) ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8: 37-45.
32. Lavin MF, (2008) Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 9: 759-769.
33. Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68: 1636-1644.
34. Liu X, Matsuda A, Plunkett W, (2008) Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther 7: 133-142.
35. Liu X, Guo Y, Li Y, Jiang Y, Chubb S, et al. (2005) Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 65: 6874-6881.
36. Cortez D, (2003) Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases. J Biol Chem 278: 37139-37145.
37. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, et al. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768.
38. Fluckiger-Isler R, Kux E, Walter P, (1996) 5-Iodotubercidin and proglycosyn: a comparison of two glycogenic compounds in hepatocytes from fasted rats. Biochim Biophys Acta 1311: 77-84.
39. Fluckiger-Isler RE, Walter P, (1993) Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin. Biochem J 292: 85-91.
40. Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G, et al. (1993) New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation. J Med Chem 36: 3424-3430.
41. Fassett JT, Hu X, Xu X, Lu Z, Zhang P, et al. (2011) Adenosine kinase regulation of cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 300: H1722-1732.
42. Peart J, Matherne GP, Cerniway RJ, Headrick JP, (2001) Cardioprotection with adenosine metabolism inhibitors in ischemic-reperfused mouse heart. Cardiovasc Res 52: 120-129.
43. Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, et al. (2005) Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psychiatry 57: 617-623.
44. Pignataro G, Simon RP, Boison D, (2007) Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. J Cereb Blood Flow Metab 27: 1-5.
45. Jiang N, Kowaluk EA, Lee CH, Mazdiyasni H, Chopp M, (1997) Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur J Pharmacol 320: 131-137.
46. Gouder N, Scheurer L, Fritschy JM, Boison D, (2004) Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 24: 692-701.
47. Di Micco R, Sulli G, Dobreva M, Liontos M, Botrugno OA, et al. (2011) Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol 13: 292-302.
48. Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, et al. (2010) Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 12: 1205-1212.